Indapta Therapeutics, a Houston, TX and Seattle, WA-based clinical stage biotechnology company, raised $22.5M in funding.
The round was led by RA Capital Management, LP, Leaps by Bayer, Vertex Ventures HC, Pontifax, and the Myeloma Investment Fund.
The company intends to use the funds to accelerate the clinical development of its differentiated allogeneic Natural Killer (NK) cell therapy.
Led by CEO Mark Frohlich, Indapta is a company focused on developing and bringing to market a diverse pipeline of cell therapies to treat the still unmet medical needs of patients with blood and solid-tumor cancers as well as autoimmune diseases. Its proprietary platform of naturally-occurring g-NK cells is specifically designed to create highly potent, more accessible, and scalable cell therapies
Indapta has completed enrollment in the safety run-in portion of the Phase 1 clinical trial of IDP-023 in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM), in which patients received up to three doses of IDP-023 without and with interleukin (IL)-2. Enrollment of cohorts receiving IDP-023 in combination with monoclonal antibodies targeting CD20 or CD38 is underway.
